

BUSINESS CONTINUITY POLICY

At Suven Pharmaceuticals Limited, we are committed to maintaining ongoing operations, enhancing governance protocols, attaining enduring strategic objectives, and safeguarding shareholders' interests. With robust capabilities, we are poised to navigate through challenging circumstances effectively.

Our commitment:

- We are committed to adhering to all pertinent laws, regulations, standards, and statutory requirements that govern our operations.
- We prioritize the identification, assessment, and mitigation of both internal and external risks and opportunities that pose potential threats to critical operations, ensuring their uninterrupted continuity.
- Conducting a Business Impact Analysis (BIA) within our Risk Management Framework allows us to pinpoint the vital activities essential for sustaining our business operations. Our risk assessment concentrates on safeguarding these critical functions of the organization.
- We implement a comprehensive Business Continuity Plan (BCP) across all Business Units, aligning with the guidelines set forth by the National Disaster Management Authority for effective disaster management.
- We engage in resource planning to ensure the allocation of sufficient resources to support the critical functions and activities of the business.
- By proactively enhancing internal systems and capabilities, we aim to meet stakeholders' expectations for business continuity effectively.
- We prioritize continuous learning and improvement to strengthen our Business Continuity Policy.

The policy applies to all Suven Pharmaceuticals Limited sites. It is a collective responsibility of the Management and Employees for implementation of this policy requirement. The policy is reviewed once in 3 years or when there is a significant change. Policy is displayed at each site, department and in the Company website. We ensure effective communication of the policy, provide training to key stakeholders, and assess organizational readiness through mock drills and internal audits.

Date: 25.04.2024 Place: Hyderabad Dr. V PRASADA RAJU MANAGING DIRECTOR

V-00

Suven Pharmaceuticals Limited

Registered Office: # 215, Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai 400093, Maharashtra, India. Tel: 91 22 61539999

Corporate Office: #202, A-Wing, Galaxy Towers, Plot No-1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad-500081 Telangana, India. Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236